Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 56.01 yuan, reflecting a 0.81% increase as of February 26, 2026, with significant trading activity and mixed capital flow [1][2]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2]. - The net profit attributable to shareholders reached 260 million yuan, up 3.3% year-on-year, while the net profit excluding non-recurring items was 222 million yuan, increasing by 1.46% [2]. - In Q3 2025 alone, the company achieved a quarterly revenue of 902 million yuan, marking a substantial year-on-year growth of 30.72% [2]. - The quarterly net profit attributable to shareholders was approximately 92.83 million yuan, reflecting a 38.68% increase year-on-year, and the net profit excluding non-recurring items was about 85.80 million yuan, up 62.68% [2]. - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2]. Market Activity - As of February 26, 2026, the stock experienced a net inflow of 5.01 million yuan from institutional investors, accounting for 5.31% of the total trading volume, while retail investors saw a net outflow of 8.79 million yuan, representing 9.3% of the total [1]. - Over the past 90 days, four institutions have issued buy ratings for Kefu Medical, with an average target price of 5.384 yuan [3].
股票行情快报：可孚医疗（301087）2月26日主力资金净买入501.59万元